Abstract Entorhinal cortex displays a distinctive organization in layer II and forms small elevations on its surface called entorhinal verrucae. In Alzheimer's disease, the verrucae disappear due to neurofibrillary tangle formation and neuronal death. Isosurface models were reconstructed from high-resolution ex vivo MRI volumes scanned at 7.0 T and individual verruca were measured quantitatively for height, width, volume, and surface area on control and mild Alzheimer's cases. Mean verruca height was 0.13 ± 0.04 mm for our cognitively normal (controls) sample set whereas for mild AD samples mean height was 0.11 mm ± 0.05 mm (p \ 0.001) in entorhinal cortex (n = 10 cases). These quantitative methods were validated by a significant correlation of verrucae height and volume with qualitative verrucae ratings (n = 36 cases). Entorhinal surfaces were significantly different from other cortical heights such as, cingulate, frontal, occipital, parietal and temporal cortices. Colocalization of verrucae with entorhinal islands was confirmed in ex vivo MRI and, moreover, verrucae ratings were negatively correlated to Braak and Braak pathological stage. This study characterizes novel methods to measure individual entorhinal verruca size, and shows that verrucae size correlates to Alzheimer's pathology. Taken together, these results suggest that verrucae may have the potential to serve as an early and specific morphological marker for mild cognitive impairment and Alzheimer's disease.
Introduction
The reliability of memory depends on an intact neuroanatomical system in the medial temporal lobe that includes entorhinal cortex and hippocampus [12, 51] . In Alzheimer's disease (AD), neurons in the entorhinal cortex, particularly those in layer II, begin to die and some leave behind a pathological marker-the neurofibrillary tangle (NFT) [27, 29] . NFTs and significant cell death characterize the neuronal loss in AD where NFTs and subsequent atrophy have been correlated with dementia [2, 19, 41] . The presence of NFTs and concomitant neuronal death represent a disease-related process and not an age-related decline [21, 26] .
In many human brains, entorhinal layer II bulges out on the entorhinal surface and causes small bumps, presumably due to large neuronal cell bodies beneath [46, 52] . Although anatomists described them as 'hippocampi verrucae' a century ago [30, 40] , few reports since then have studied the verrucae. Simic and colleagues [43] described that the number of entorhinal verrucae increased with age and that overall verrucae area decreased during aging.
Solodkin and Van Hoesen [44] correlated verrucae destruction to AD in pathological specimens. Thus, in AD, entorhinal cortex undergoes massive atrophy and the entorhinal verrucae disappear. The demise of entorhinal cortex and hippocampal CA1 has been correlated to mild cognitive impairment [9, 26] and this suggests that the destruction of entorhinal layer II occurs at or before mild cognitive impairment when therapeutic effects can be most beneficial. Since NFTs in entorhinal layer II lie directly underneath entorhinal verrucae, the verrucae represent a presumptive morphological neuroimaging marker for AD.
Recent advances in MRI have allowed detection of cytoarchitectural features in the human brain [7, 13] and in particular entorhinal layer II in high-resolution (100 lm 3 ) ex vivo MRI [4] . To determine the individual verruca size, we developed an algorithm to measure height, volume, surface area and width on isosurface reconstructions from our medial temporal lobe ex vivo MRI. Our results confirm that entorhinal cortex surface differs from other cortical surfaces, and that a 3D spatial relationship exists between entorhinal islands and entorhinal verrucae as observed in ex vivo MRI. Moreover, we found that verrucae from mild AD cases were smaller than normal control surfaces in entorhinal cortex, and that verrucae size correlated to Braak and Braak staging. This model elucidates the magnitude of entorhinal verrucae in normal controls and AD and relates their size to disease severity. These results demonstrate a significant correlation between entorhinal verrucae size and AD pathology and points to a specific morphological marker in normal controls and mild AD.
Methods

Brain samples
Thirty-six entorhinal cortex samples were obtained from the Massachusetts General Hospital Alzheimer's Disease Research Center or Massachusetts General Hospital Autopsy Service. In addition, we obtained eight additional cortical samples (motor, occipital, fusiform, Wernicke's, frontal, cingulate) that we imaged to serve as a surface control (i.e., not diagnostic control) to show verrucae are unique to entorhinal cortex, and to validate our quantitative model. Most of the neocortical and cingulate samples were obtained from the same control cases as medial temporal samples. Samples were either fixed with 10% formalin from Autopsy Service or 4% paraformaldehyde from our Alzheimer's Disease Research Center for at least 2 weeks. Postmortem interval was less than 48 h and samples included 20 males, 14 females, 2 with gender information unavailable, with age ranging from 43 to 102 years (mean 76 years). We further describe demographic and diagnosis information in Table 1 . Clinical diagnoses listed in Table 1 were received from the Memory Disorders Unit in Department of Neurology at the Massachusetts General Hospital. Non-Alzheimer's dementias were excluded from this study. Of the 36 entorhinal samples, all were evaluated for verrucae rating assay (n = 36), but a subset of this group was examined for the verrucae metric assay (n = 10). 10 a n/a n/a LH \24 AD, B&B I Control 11 a 60 M RH \24 AD, B&B I Control 12 a n/a n/a LH \24 AD, B&B II Control   13  95  M  RH  20  AD, B&B III Control   14 a 86  F  LH  18  AD, B&B III AD  15  79  F  LH  6  AD, B&B III AD   16  87  M  RH  n/a  AD, B&B III AD   17  87  M  LH  48  AD, B&B IV AD   18  82  F  RH  12  AD, B&B IV AD   19  89  M  RH  14  AD, B&B IV AD   20  84  M  RH  10  AD, B&B V  AD   21  90  F  RH  24  AD, B&B V  AD   22  93  F  RH  15  AD, B&B V  AD   23  77  M  LH  48  AD, B&B V  AD   24 102 M n/a n/a AD, B&B V AD [4] . We have further optimized the MRI parameters, but maintained 100 lm 3 resolution, and acquired images with TR = 54 ms, TE = 25 ms, bandwidth = 30 Hz/pixel, 650 9 440 matrix that improved signal-to-noise ratio. Images were acquired with flip angles 10°, 20°and 30°and three FLASH images were averaged to generate a mean for each flip angle. In a subset of cases (n = 10), samples were scanned in hydrogen-free Fomblin (Solvay, Houston, TX, USA) in order to generate a clean surface reconstruction without surrounding liquid necessary for verrucae quantitative measurements. Gross photographs were captured with a Canon EOS Digital Rebel XT (8 MP) with a 50-mm lens.
Isosurface reconstruction
Three-dimensional isosurfaces of the entorhinal cortex were reconstructed from the MR volume with two different software packages to test reliability of our method. We used Freeview (Freeview, a visualization tool that is part of the FreeSurfer package, http://www.surfer.nmr.mgh. harvard.edu) and Amira (Amira, Berlin, Germany) to generate isosurfaces of entorhinal cortex and other cortices that were examined. In both, the cortical surface extraction was automated [14] and entorhinal surfaces were reconstructed from FLASH images at 100 lm 3 resolution with 20°flip angle. Although the visualization tools in Freeview and Amira implement different volume rendering schemes, both produced satisfactory isosurfaces. For convenience with our Linux-based MRI volumes, we used Freeview for all measurements in this report. Throughout this report, we use the terms isosurface and surface interchangeably.
Quantitative and qualitative verrucae surface assays
Quantitative surface assay
We selected verrucae that were measured using a systematic random sampling method. We used a transparent grid overlay that was 6 9 5 squares (30 total squares) and the overall grid measured 13.5 cm 9 11.25 cm. Each individual box or square was 2.25 cm 9 2.25 cm and had exclusion lines (bottom and left) and inclusion lines (top and right). Each surface reconstruction was zoomed so that the total grid (30 squares) covered the entorhinal surface at approximately the level of the amygdala where the grid was overlaid with the top aligned at the medial border of EC (nearly parallel with the hippocampal fissure) in every case. Visibly identifiable verrucae were labeled within each randomly selected grid square (i.e., we did not label random non-verrucae patches). We used a random number generator to determine which ten counting squares to label per case. Each case required approximately 30 min for manual labeling. This procedure generated a verrucae sample size, n = 165, for the quantitative verrucae measurements. Next, we analyzed the labels (or patches) with our 'verrucae metric' algorithm in MATLAB (MATLAB, MathWorks, Natick, MA, USA) that computed the optimal least-squares fitting plane at the base of the surface, and then measured for height, width, volume, and surface area of each surface patch. Height measurements were determined as the maximum perpendicular distance from the fitted plane at the base of the verruca to the isosurface (see schemata in Fig. 3d ). Width was determined as the maximum diameter of the label and surface area was calculated as the sum of labeled triangles. Volume measures the space above the base-fitting plane and was computed as the sum volumes of the polyhedra obtained by projecting each of the surface triangles onto the base fitting plane. We obtained very slight differences in verrucae measurements between Amira and Freeview and attribute this variation to the different tessellation algorithms employed by each software package. These differences were not significant when compared using an independent samples t test.
Qualitative surface rating
Verrucae surface reconstructions were validated with photography of gross brains and a qualitative verrucae rating scale was developed for reliability. The qualitative rating protocol was created to assess verrucae magnitude in graded categories. The verrucae rating protocol consisted of 5 ranking categories: 1 = no verrucae (flat surface), 2 = verrucae are barely visible and very small, 3 = a few small and medium-sized verrucae are present, 4 = many small and medium size verrucae are present and finally 5 = several large prominent verrucae are present. Examples illustrate each rating category through gross photographs ( Fig. 1) . We developed the qualitative scale not only to establish reliability but also to avoid placing Alzheimer's Disease Research Center cases in Fomblin. Two raters (rater #1 = JCA and rater #2 = KEH) evaluated photographs for qualitative verrucae assessment and ratings were averaged for overall mean.
Neuropathology analysis
All cases were stained with Nissl (thionin) for healthy cell bodies and thioflavine S to assess the presence of neurofibrillary tangles and senile plaques. Nissl staining was performed as previously published [4] and thioflavine S was performed according to Van Hoesen [55] . In brief, Nissl stains were pretreated and defatted. Subsequently, the sections were stained with 0.5% aqueous thionin for 5 min. Slides were dehydrated in ascending ethanol series, cleared in xylene and coverslipped with Permount (Fisher, Fair Lawn, NJ, USA). Thioflavine S sections were defatted and stained in 0.2% solution of Thioflavine S (Sigma, St. Louis, MO, USA) and coverslipped with water soluble mounting media. Additionally, Alzheimer's pathology was assessed using Rabbit anti-human tau (Dako, Carpinteria, CA, USA) and Bielschowsky's silver stain at MGH Department of Neuropathology. A standard immunocytochemical protocol was used with bovine serum albumin for blocking non-specific binding, primary antibody (anti-tau) dilution was 1/3,000 and visualized with 3 0 ,3-Diaminobenzidine Peroxidase Substrate Kit (Vector, Burlingame, CA, USA). Bielschowsky's silver stain was adopted from University of Massachusetts Medical Center (Worcester, MA, USA). Alzheimer's disease and subsequent Braak and Braak staging was diagnosed and evaluated by neuropathologist (M.P.F. or T.S.) and J.C.A.
at Massachusetts General Hospital. Braak and Braak staging determined the severity of neurofibrillary tangles in distinct and cumulative cortices. In brief, each stage is summarized, stage I represents neurofibrillary tangles in perirhinal cortex (layer II-III), stage II displays neurofibrillary tangles in entorhinal cortex (layer II), stage III adds entorhinal layer IV and CA1, stage V includes all hippocampal CA fields and subiculum and finally stage VI occurs when neocortical areas and dentate gyrus contain neurofibrillary tangles [10] . Cytoarchitecture and neuropathology were evaluated using a fluorescence Nikon 80i microscope (MVI, Avon, MA, USA).
Statistical analysis
Non-parametric correlations (Spearman's q) were used for qualitative-quantitative reliability tests and to compare verrucae rating with Braak and Braak stage. Mann-Whitney U test was used to compare other cortical surfaces to entorhinal cortex. Mann-Whitney U test was also used to compare verrucae rating with gender, and to compare quantitative and qualitative verrucae measures between control and AD cases. Cohen's Kappa was used to assess inter-rater reliability on qualitative verrucae ratings. p value was set at p \ 0.05 for significance. Statistics were performed using SPSS (SPSS, IBM Corporation, Somers, NY, USA). 
Results
Colocalization in MRI between EC islands and verrucae
From ex vivo MRI volumes of medial temporal lobe samples, we created surface reconstructions and found that entorhinal islands (layer II) colocalized with surface verrucae (labeled in blue) in all cases that showed visible islands and verrucae (i.e., most control cases). Each 2D image is shown with a partial surface reconstruction in coronal, sagittal and axial planes (Fig. 2a, b, c) . In fastlow-angle-shot (FLASH) images in ex vivo MRI, bright intensities signify cell dense regions such as entorhinal islands in layer II. Islands were observed as spherical intensities in all views (Fig. 2) . These data confirm the spatial relationship between entorhinal islands in layer II and surface elevations and adds a 3D modularity.
Surface reconstructions validate gross morphometry
We examined surface reconstructions of entorhinal cortex in normal control and Alzheimer's samples and found that our surface model (Fig. 3b) validates what was observed in the gross specimen (Fig. 3a) . In fact, we found that the surface reconstruction improved detection of verrucae. We observed that the surface reconstructions yielded better visualization because the reconstruction improved shadowing that highlighted individual verruca and we had the ability to manually rotate the surface to illuminate all angles while evaluation with the gross photographs required more than one photo. A cognitively normal brain with entorhinal verrucae is illustrated in Fig. 3 to show the pipeline of our model. We labeled all individual verrucae on the entorhinal surface to show the extent of verrucae in a cognitively normal case (Fig. 3c) . Blue labels highlight individual verruca where entorhinal verrucae were primarily observed at the level of the amygdala and hippocampal head and to a lesser extent at posterior levels. We developed code to quantitatively evaluate the size of an individual verruca. An individual verruca schemata is shown in Fig. 3d where height, width and surface area were measured and volume was calculated. The blue label in Fig. 3c corresponds to blue label in the diagram (Fig. 3d ).
Quantitative differences in verrucae geometry between mild AD and controls
To further characterize the entorhinal verrucae, we labeled randomly selected verrucae in each case. For the quantitative measures, we found that normal control brains (n = 6; 100 labels) produced a verrucae height of 0.13 ± 0.04 mm (mean ± SD), verrucae width of 1.26 ± 0.29 mm (mean ± SD), verrucae surface area of 0.81 ± 0.37 mm 2 (mean ± SD) and verrucae volume of 0.05 ± 0.04 mm 3 (mean ± SD) ( Table 2 ). The measured verrucae size for mild AD cases (n = 4; 65 labels) for verrucae height was 0.11 ± 0.05 mm (mean ± SD), verrucae width was 1.14 ± 0.22 mm (mean ± SD), verrucae surface area was 0.70 ± 0.30 mm 2 (mean ± SD) and finally verrucae volume was 0.04 ± 0.03 mm 3 (mean ± SD) ( Table 2) . We compared these verrucae measurements between normal controls (n = 100 verrucae, per metric) and mild AD cases (n = 65 verrucae, per metric) and found that verrucae height (Mann-Whitney U test, p \ 0.001), width (Mann-Whitney U test, p \ 0.05), surface area (Mann-Whitney U test, p \ 0.05), and volume (Mann-Whitney U test, p \ 0.01) were significantly decreased in the mild AD cases compared to normal controls. In sum, the reconstructed verrucae resembled those visually observed in the gross brain and verrucae quantitative measures showed a significant change in mild AD compared to controls. Entorhinal surface significantly different from other cortical surfaces
To corroborate our measurement model, we imaged eight additional sample blocks from various other cortices and modalities such as, cingulate, frontal, occipital, parietal, temporal and motor. Since visible verrucae were not present in neocortical samples, we modeled our labels after the approximate width of our EC verrucae data to reproduce similar sized patches. We reconstructed the surfaces and randomly selected labels using the same methods as above and we found that these cortical surfaces were significantly different from entorhinal cortex in height. All heights were constrained to positive numbers and we restricted our samples and measurements to gyri (i.e., crowns) to control for overall geometry. Entorhinal heights (n = 6 cases, n = 100 labels) averaged 0.13 mm whereas motor, occipital, fusiform and Wernicke's area were all below 0.10 mm for height (i.e., motor cortex height 0.07 mm); p \ 0.001, Mann-Whitney U test, for all nonentorhinal surfaces when compared to entorhinal) (Fig. 4) , indicating a significantly flatter cortical surface in the control regions. Thus, entorhinal surfaces show significant differences from other neocortical tissue and demonstrate a more rugged topography compared to other cortical areas. Verrucae qualitative ratings correlate with verrucae height and volume
As a supplement to quantitative verrucae measurements, we also developed a qualitative rating scale for reliability and to avoid scanning all cases in Fomblin liquid. Fomblin is a proton-free liquid used to minimize background effects and helped to generate a clean isosurface. The rating scale (described in methods) ranges from 1 to 5 where rating 1 denotes a flat surface and 5 indicates several large verrucae.
We found that the quantitative measurements, height and volume, reconciled well with our qualitative rating scale and showed a significant positive correlation for height (Spearman's q = 0.883, p \ 0.01, n = 10) and volume (Spearman's q = 0.716, p \ 0.05, n = 10) (Fig. 5 ). Width and surface area measurements did not achieve significance compared to verrucae rating (width: Spearman's q = 0.469, p = 0.17, n = 10 and surface area: Spearman's q = 0.519, p = 0.13, n = 10).
Inter-rater reliability
We examined qualitative verrucae ratings with an inter-rater reliability test to evaluate the strength of our ratings. Two raters evaluated verrucae size on gross photographs and assigned a rating within 1-5 on verrucae size protocol. A verrucae rating of ''1'' means a flat cortical surface and shows no verrucae while a verrucae rating of ''5'' signifies large verrucae present across the entorhinal surface. The raters utilized and referred to the same verrucae rating protocol described in the methods. Utilizing a Cohen's Kappa, we found agreement among the two raters (Kappa = 0.38, p \ 0.001).
Verrucae size correlates with Braak and Braak stage
Next, we compared photographs and surface reconstructions in normal control (Fig. 6a, b ) and Alzheimer's cases (Fig. 6c, d ). We rated verrucae (based on qualitative protocol) and tested the verrucae ratings against pathological diagnosis. We confirmed that the MRI reconstructions represented the verrucae precisely and provided validation for the gross or photographic surfaces. Our rating results corroborate our quantitative measurements described above where we quantified verrucae size in a subset of cases. With a significant difference in quantitative verrucae measures between controls and mild AD samples, we next examined the pathological marker in AD. To assess pathological diagnosis, we stained for neurofibrillary tangles and amyloid plaques with thioflavine S and staged each case based on Braak and Braak criteria for neurofibrillary (Fig. 7) (p \ 0.01, Spearman's q = -0.526, n = 36). Furthermore, we also found that verrucae ratings were significantly different when comparing normal controls to AD severity in increments. Normal controls had significantly higher ratings than Braak and Braak stage III and IV (Mann-Whitney U test, p \ 0.001) and Braak and Braak stage V and VI (Mann-Whitney U test, p \ 0.001). Verrucae ratings were not significantly different between normal controls and Braak and Braak stage I and II (Mann-Whitney U test, p = 0.084) but these groups showed a significantly difference in our quantitative results (height, volume, width and surface area) with mild AD cases decreased compared to controls.
Age, gender, post mortem interval and fixative
Within the normal control group, we did not observe a relationship between verrucae and age, gender, postmortem interval nor fixation in paraformaldehyde or formalin. Postmortem interval is the time that passes between death and time of fixation of the brain. It could be a concern that the verrucae collapse after death but we did not find that postmortem interval showed any relationship with the overall size of the verrucae (Spearman's q = 0.274, p = 0.42, n = 11). Among our cases, we found that no significant difference between male and female entorhinal cortices (Mann-Whitney U test, p = 0.82). We were unable to examine laterality with our sample set because we did not obtain both hemispheres. We scrutinized the samples to determine whether formalin or paraformaldehyde had an effect on verrucae size but did not observe a difference qualitatively. As described above, we observed a height difference in verrucae between normal controls and AD samples in our quantitative measurements that were all within the formalin-fixed group which precludes technical differences between fixatives. In addition, we did not observe any tissue differences between fixatives and all cases were well preserved. All cases sectioned and stained properly and nothing remarkable was observed in MRI or histology concerning fixation.
Discussion
In a previous study, we demonstrated that layer II islands are visible in the entorhinal cortex using ex vivo MRI [4] and that these islands could be used to localize entorhinal cortex in vivo [18] . Here, we built on this model, and created entorhinal surface reconstructions to quantify spatial and morphometric properties of the verrucae. Utilizing ex vivo MRI, we confirmed that entorhinal islands colocalize with entorhinal verrucae, i.e., that each island is beneath a verruca, as originally detailed previous neuroanatomical studies [30, 40, 44, 54, 55] . We validated our model with qualitative assessment in the gross specimen and showed that verrucae measurements accurately reflect their true size. The validated models were then used to demonstrate that entorhinal surfaces in control cases differed significantly from other cortical regions. Finally, with this morphometric model, we determined that entorhinal verrucae in control cases were significantly larger than mild AD cases, and that verrucae size significantly and negatively correlated to Braak and Braak stage determined by NFTs in all stages.
The novelties of our study include unique application of imaging methods on entorhinal surface reconstructions (i.e., new model development), quantitative demonstration of individual verruca size (height, width, surface area and volume), establishment of verrucae ratings or grades (i.e., qualitative assessment of verrucae in control and Alzheimer's disease cases) and finally correlation of verrucae rating to Braak and Braak neurofibrillary tangle stages. No prior study has described individual verruca size quantitatively, or its correlation to AD severity and with highresolution imaging methods.
Visible to the unaided eye, neuroanatomists described entorhinal verrucae a century ago [30, 40] . The human eye (20/20 vision) can resolve objects about 0.1 mm long which is consistent with our verrucae measurements of approximately 0.13 mm in height (mean) and 1.26 mm in width (mean) for control cases. In AD, however, verrucae become atrophic and shrink, and are not observed in severe cases [44, 53, 55] . Our results confirm these findings, and demonstrate that a semi-automated model derived from neuroimaging data can provide a quantitative assessment of individual verrucae sensitive enough to detect and quantify AD-related atrophy even in its mildest stage.
We compared our findings from entorhinal cortex to neocortical and other limbic surfaces to demonstrate that the method utilized is specific to regions of the brain containing verrucae. The lack of height in neocortical areas demonstrates that our quantitative measures correspond to what can be observed visually. It is noteworthy that since our voxel size represents isotropic data at 100 lm 3 and since verrucae means were 0.13 and 1.26 mm for control cases, each verrucae measurement symbolizes several (*13) voxels in width and at minimum 1 voxel in height. In our mild AD cases, verrucae width (mean) was 1.14 mm and height was 0.11 mm and contained several (*11) voxels in width and at minimum 1 voxel in height. Given this relationship and high resolution, we avoid partial voluming issues even in mild AD cases as quantitative measurements were not performed on severe cases.
Prior work has examined entorhinal verrucae. Our data demonstrate a decrease in verrucae size with a disease process (Alzheimer's disease) whereas the Simic and colleagues [43] examined normal aging. These two studies examined different matters. The extensive study by Simic which used molded casts reported the total number of verrucae on the surface, overall entorhinal surface area and counted neurons in non-demented aging. Our study quantified the size of individual verrucae (height, width, volume and surface area) and compared the size to Alzheimer diagnosis and severity (Braak and Braak stage). Additionally, the prior study examined a sample of tissue spanning a wide range of adult life from age 23 to 85 and found 60 cases had neither cognitive impairment (i.e., normal controls and/or normal aging) nor neurological incident. In the current study, NFTs were correlated with verrucae morphology. It could be postulated that verrucae increase in total number during aging from cross-sectional data [43] but once the Alzheimer's cascade begins, then the verrucae decrease in size and eventually disappear due to neuronal loss that gives way to neurofibrillary tangles. Alternatively, Simic and colleagues suggested that verrucae may split into smaller verrucae and that may account for the increase in total number of verrucae during aging. With regard to normal aging, the Simic study remains the most significant report to date cataloging the number of verrucae as a function of age, and has provided the best examination of verrucae in younger persons and healthy older adults with most of their samples gifted from individuals without neurodegenerative diseases. Our study further characterized the verrucae trajectory in Alzheimer's disease and showed differences in verrucae size, suggesting that verrucae height and volume were the most affected in our AD samples and related to disease severity. We further showed that all verrucae measures were significantly different in mild AD compared to normal controls. Taken together, these results begin to establish the normal architecture and magnitude of the verrucae in healthy aging and AD.
We speculate that the mechanisms that account for the reduction of verrucae are neuronal loss, neuronal shrinkage due to neurofibrillary tangles and/or decreased synaptic connections in entorhinal cortex layer II. Neurofibrillary tangles are typically smaller in size than a functioning healthy neuron [28, [33] [34] [35] so that decrease could account for the decrease in verrucae size we observed in AD. Neuronal diameter measurements have been reported in AD where decreased neuronal diameter was demonstrated in AD compared to controls and that neuronal size was 30% smaller in neurons with neurofibrillary tangles [34, 35] . Decreased neuronal measurements have also been observed in the aging brain in neocortical areas, especially frontal and temporal areas [48, 49] . It is important to note that that the presence of a neurofibrillary tangle means that a neuron has died [56] and that neurofibrillary tangles indicate neuronal loss [5, 21] . Age-related and Alzheimer's-related neuronal loss has been reported [20, 21, 25, 26, 32, 43, 48] , but future studies will have to determine whether or not verrucae size relates to stereologically defined neuronal loss. Since Braak and Braak [10] staging is based on the presence of neurofibrillary tangles in the medial temporal lobe and given the fact that neurofibrillary tangles have been strongly correlated to clinical dementia by several groups [2, 9, 19, 21, 32] and in large sample studies [41] , we consider using Braak and Braak staging to assess the severity of cases the closest pathological metric to cognitive behavior. There is little doubt that the presence of neurofibrillary tangles, more than a few isolated tangles, signifies the person has memory impairment [36] . Synaptic degeneration is also a variable in AD and several studies have demonstrated decreases in the number of synapses [1, 37, 47] , and decreases in synaptic proteins (i.e., synaptophysin) [11, 24, 45] in hippocampus and entorhinal cortex in AD, notably early in disease progression. Some evidence suggests that decreases in synaptic density occur after age 65 [38] and others have demonstrated a correlation between dystrophic neurites and severity of dementia [6, 45] . Even so, neuronal cell death is likely the principal basis for the reduction in verrucae size with a smaller contribution due to other mechanisms such as synaptic degeneration. It is possible that collectively these mechanisms may be responsible for the reduction in verrucae size in AD.
Given that cases with large verrucae were less likely to have AD, our results beg the question; do large verrucae represent cognitive resilience and healthy aging? It is unquestionable that cognitive resilience, or cognitively normal cases with AD pathological changes, is an existing, albeit small, category in neuropathology [8, 15, 17, 23, 39, 42] . Even in cognitively normal cases, most of our cases contained a few NFTs and this was consistent with existing studies that have described NFTs in aging [3, 23, 31] . The density of NFTs and decreased neuronal numbers remain reliable correlates that predict dementia [2, 19, 20, 26] . Our results suggest that verrucae height measures below 0.12 mm predict a mild AD diagnosis. Given that we observed the largest height in an individual verrucae was 0.25 mm and that verrucae in mild AD cases were typically below 0.12 mm and that flat cortex is less than 0.10 mm, a quantitative range exists that may correspond to cognitively healthy aging and mild cognitive impairment. Variability in neurofibrillary tangles, early in the disease, has been reported in Alzheimer's disease [22] . Currently, it is unknown what accounts for this variability in verrucae size. This may be explained by cognitive resilience where variation in verrucae size across cases may account for categorical groups: AD (Alzheimer's dementia), frail (dementia without neuropathological markers), cognitive resilience (no clinical dementia but with neuropathological markers), and normal controls (cognitively normal and no pathological markers). Future studies will have to establish these relationships with cognitive and behavioral data. Nonetheless, the characterization of verrucae not only contributes to understanding a biological phenomenon but also establishes verrucae absence as a metric for earlier AD diagnosis and may provide initial evidence for the future cognitive resilience hypotheses.
While the resolution used here is not achievable using current clinical in vivo technology, further characterization of verrucae with ex vivo methods allows us to define the neural correlates of this unique structure, and examine the variability between individuals. Verrucae detection will require isotropic voxels that will challenge neuroimaging technologies as structures require 3D assessment. Nevertheless, neuroimaging continually improves resolution and acquisition techniques such as motion correction or phase imaging that may advance avenues of early detection [16, 50] . Most importantly, the correlation of histology and ex vivo MR imaging provides a tool for validation with many proteins, neurons and pathological states and these results offer a bridge to applying these tools to in vivo imaging when available.
In summary, our data indicate that verrucae changes, particularly in height and volume, may reflect the pathological presence of NFTs (i.e., neuronal loss) and provide a morphological marker to diagnose AD. Entorhinal verrucae represent a highly specific structural marker for detecting AD early in the course of the disease, and provide a potentially sensitive marker for future neuroimaging. The capacity to determine localized changes in relation to pathology may have considerable repercussions in terms of clinical diagnosis of AD and the future applications of this technique could identify changes in other disorders as well.
